Lincoln Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Lincoln Pharmaceuticals is strategically transitioning from a volume-driven acute care model to a diversified, high-value manufacturer, focusing on chronic and lifestyle therapeutic segments. Management's emphasis on global market penetration, supported by recent TGA and EU-GMP certifications, positions the company to expand into regulated markets like Canada, enhancing its competitive position. The capacity expansion at the Mehsana Cephalosporin facility and the new Bulk Drug Manufacturing plant are expected to drive revenue growth over the next 24 months. Vista's financial outlook reflects stable revenue growth consistent with historical performance, although margins are anticipated to face pressure due to rising input costs. The company's net debt-free balance sheet supports financial stability, aligning with Vista's fair valuation assessment. While the Indian pharmaceutical sector is expanding, benefiting from favorable currency dynamics and a strong pipeline of innovative products, Lincoln must navigate challenges related to working capital intensity and regulatory compliance. Over the next 12-24 months, key opportunities include leveraging export growth and R&D-led innovation, while watchpoints include potential margin pressures and the competitive landscape dominated by larger players
Why We Like This Stock
- Strategic shift towards high-value chronic and lifestyle therapeutic segments enhances revenue potential
- Recent capacity expansions and certifications facilitate entry into regulated markets, broadening market reach
- Strong liquidity and a net debt-free balance sheet provide financial stability for future investments
Things To Watch Out For
- Margins are expected to remain under pressure due to rising input costs and working capital intensity
- Regulatory compliance risks associated with global market expansion could impact operational efficiency
- The competitive landscape is fragmented, with larger players dominating key segments, posing challenges for market share growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 581 | 623 | 671 | 709 | 759 |
| Profit Before Tax (Cr.) | 121 | 107 | 116 | 145 | 149 |
| PBT Margin | 20.8% | 17.2% | 1728.8% | 20.5% | 19.7% |
| Net Profit (Cr.) | 96 | 83 | 88 | 110 | 114 |
| Earnings Per Share | 47.8 | 41.4 | 43.9 | 55.1 | 56.7 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.